α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Accumulating evidence suggests that α7 nicotinic receptors (α7 nAChRs), a subtype of nAChRs, play a role in the pathophysiology of neuropsychiatric diseases, including schizophrenia and Alzheimer’s disease (AD). A number of psychopharmacological and genetic studies shown that α7 nAChRs play an important role in the deficits of P50 auditory evoked potential in patients with schizophrenia, and that (α nAChR agonists would be potential therapeutic drugs for cognitive impairments associated with P50 deficits in schizophrenia. Furthermore, some studies have demonstrated that α7 nAChRs might play a key role in the amyloid-β (Aβ)-mediated pathology of AD, and that α7 nAChR agonists would be potential therapeutic drugs for Aβ deposition in the brains of patients with AD. Interestingly, the altered expression of α7 nAChRs in the postmortem brain tissues from patients with schizophrenia and AD has been reported. Based on all these findings, selective α7 nAChR agonists can be considered potential therapeutic drugs for cognitive impairments in both schizophrenia and AD. In this article, we review the recent research into the role of α7 nAChRs in the pathophysiology of these diseases and into the potential use of novel α7 nAChR agonists as therapeutic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 9×
“Genetic linkage analysis of deficits in P50 auditory evoked potential in families of patients with schizophrenia has revealed a peak LOD score at 15q13-q14, and the LOD score was 5.3 (theta=0.00) at the D15S1360 marker, which is located in intron 2 of the gene for the 7 nAChR subunit (CHRNA7) [58].”
BackgroundInfluentialFlores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
Schizophrenia, sensory gating, and nicotinic receptors
Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., et al. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033320 · Cited by 690
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“This parallels studies of postmortem human tissue that documented a decreased expression of hippocampal 7 nAChRs in schizophrenic patients [45].”
BackgroundPharmacology of Nicotine: Addiction and Therapeutics
Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589 · cited 1×
“In addition, recent attention has been directed to the potential role of nAChRs in diseases and therapeutic targets [10-23].”
BackgroundNeurobiological studies of sensory gating in schizophrenia
Freedman, R., Adler, L. E., Gerhardt, G. A., Waldo, M., Baker, N., Rose, G. M., Drebing, C., Nagamoto, H., Bickford-Wimer, P., & Franks, R. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.4.669 · Cited by 430 · cited 1×
“Normal subjects, however, have significantly reduced responses to the second stimulus [44, 52, 54, 55].”
BackgroundInitial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Nicotinic receptors in the brain. Links between molecular biology and behavior
Picciotto, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00146-3 · Cited by 354
Nicotinic receptor subtypes and cognitive function
Levin, E. D. (2002) · Journal of Neurobiology · doi:10.1002/neu.10151 · Cited by 354
Nicotine addiction: the possible role of functional upregulation
Buisson, B., & Bertrand, D. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01979-9 · Cited by 254 · cited 1×
“The health consequences of smoking and the mechanisms involved in nicotine dependence continue to be subjects of great interest [5-9].”
Background
Cited by
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
“In addition, KA is a known endogenous antagonist at α7 nicotinic acetylcholine receptors (nAChR) which are implicated in the pathophysiology of neuropsychiatric disorders [73-79].”
Self-citationNicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R., Rollema, H., & Bertrand, D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 522
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
The vagal innervation of the gut and immune homeostasis
Matteoli, G., & Boeckxstaens, G. E. (2013) · Gut · doi:10.1136/gutjnl-2012-302550 · Cited by 276
Metadata
- Authors
- Toyohara, J., & Hashimoto, K.
- Venue
- The Open Medicinal Chemistry Journal
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-05-27
- Volume
- 04
- Issue
- 1
- Pages
- 37-56
- ISSN
- 1874-1045 (ISSN-L)
- OpenAlex
- W2053459721
- Cited by
- 108
- References
- 13
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease. https://app.cochat.ai/papers/10.2174/1874104501004010037
- The paper
- Toyohara, J., & Hashimoto, K. (2010). α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease. The Open Medicinal Chemistry Journal. https://doi.org/10.2174/1874104501004010037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.